SCHEMBL1649084

SCHEMBL1649084

O=C(O)CC(c1ccc(Cl)cc1)c1c(O)c2ccccc2oc1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 5/20 0.70
CYP2C9 P11712 9/20 0.67
HSD17B10 Q99714 2/20 0.67
ALB P02768 2/20 0.67
VKORC1 Q9BQB6 2/20 0.67
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 1/20 0.67
PCSK7 Q16549 1/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
CYP3A4 P08684 1/20 0.66
NR1I2 O75469 1/20 0.59
NR3C1 P04150 1/20 0.59
ADRA1A P35348 1/20 0.59
KCNH2 Q12809 1/20 0.59
TOP1 P11387 1/20 0.59
TOP2A P11388 1/20 0.57
CRHBP P24387 1/20 0.56
CASP7 P55210 1/20 0.56
CASP6 P55212 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1649909 0.91 CYP2C9 (0.80) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL3480693 0.90 CYP2C9 (0.59) NQO1CYP2C9HSD17B10ALBVKORC1
Coumachlor SCHEMBL30930052 0.90 CYP2C9 (0.84) NQO1CYP2C9HSD17B10ALBVKORC1
Coumachlor SCHEMBL433455 0.90 CYP2C9 (0.84) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL3177410 0.87 CYP2C9 (0.60) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL3174704 0.87 CYP2C9 (0.60) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL3158084 0.87 CYP2C9 (0.60) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL7406235 0.86 CYP2C9 (0.82) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL7077173 0.85 CYP2C9 (0.61) NQO1CYP2C9HSD17B10ALBVKORC1
SCHEMBL3168033 0.84 NQO1 (0.72) NQO1CYP2C9HSD17B10ALBVKORC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161261-B1 Materials and methods for treating coagulation disorders ARMETHEON INC (US) 2013-08-28 EP disclosed
US-7932405-B2 Halogenated ester derivatives of coumarins for the treatment of coagulation disorders ARYX THERAPEUTICS, INC. (US) 2011-04-26 US disclosed
EP-2161261-A1 Materials and methods for treating coagulation disorders Aryx Therapeutics (US) 2010-03-10 EP disclosed
EP-1735296-B1 MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS ARYX THERAPEUTICS (US) 2009-12-09 EP disclosed
US-20090082430-A1 Materials and Methods for Treating Coagulation Disorders ARYX THERAPEUTICS, INC. (US) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082430-A1 Materials and Methods for Treating Coagulation Disorders F12, F2, SERPINC1 NQO1 390/4885CYP2C9 553/4885HSD17B10 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.